Data Sheet

Product Name:	Lisinopril (dihydrate)
Cat. No.:	CS-2444
CAS No.:	83915-83-7
Molecular Formula:	C21H35N3O7
Molecular Weight:	441.52
Target:	Angiotensin-converting Enzyme (ACE)
Pathway:	Metabolic Enzyme/Protease
Solubility:	DMSO : < 1 mg/mL (insoluble or slightly soluble); H2O : 20 mg/mL (45.30 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

Lisinopri (dihydrate) (IMK-521 (dihydrate)) is angiotensin-converting enzyme inhibitor, used in treatment of hypertension, congestive heart failure, and heart attacks. . IC50 & Target: ACE. **In Vitro:** Lisinopri (dihydrate) (IMK-521 (dihydrate)) is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy[1][2].

References:

[1]. Andujar-Sanchez, M., V. Jara-Perez, and A. Camara-Artigas, Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett, 2007. 581(18): p. 3449-54.

[2]. Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41(3): p. 207-24.

CAIndexNames:

L-Proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-, hydrate (1:2)

SMILES:

O=C(O)[C@H]1N(C([C@H](CCCCN)N[C@H](C(O)=O)CCC2=CC=CC=C2)=O)CCC1.O.O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA